Cargando…

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

BACKGROUND AIMS: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. We aimed to elucidate the incidence, clinical and laboratory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qiqi, Zu, Cheng, Jing, Ruirui, Feng, Youqin, Zhang, Yanlei, Zhang, Mingming, Lv, Yuqi, Cui, Jiazhen, Zhou, Linhui, Meng, Ye, Wang, Linqin, Cen, Zenan, Chang, Alex H., Hu, Yongxian, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192732/ https://www.ncbi.nlm.nih.gov/pubmed/37215107 http://dx.doi.org/10.3389/fimmu.2023.1125357

Ejemplares similares

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells
por: Dai, Ying, et al.
Publicado: (2023)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
por: Ding, Shuyi, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma
por: Hong, Ruimin, et al.
Publicado: (2021)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

Rewiring T-cell responses to soluble factors with chimeric antigen receptors
por: Chang, ZeNan L., et al.
Publicado: (2018)

PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023)

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
por: Yang, Yingying, et al.
Publicado: (2018)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors
por: Chang, ZeNan L., et al.
Publicado: (2015)

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
por: Zhao, Wan-Hong, et al.
Publicado: (2018)

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment
por: Zhou, Linghui, et al.
Publicado: (2021)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

A compound chimeric antigen receptor strategy for targeting multiple myeloma
por: Chen, K H, et al.
Publicado: (2018)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
por: Hu, Yongxian, et al.
Publicado: (2018)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
por: Hu, Dingyuan, et al.
Publicado: (2023)

Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
por: Feng, Jingjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k5iggtvpb1aenaonf355flatr3